Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;6(12):3595-3596.
doi: 10.1002/hep4.2047. Epub 2022 Jul 12.

Response to immunotherapy plus anti-angiogenic agent combination challenges hepatocellular carcinoma prognostic scores

Xavier Adhoute  1 , Thomas Wolf  1
Affiliations
Comment

Response to immunotherapy plus anti-angiogenic agent combination challenges hepatocellular carcinoma prognostic scores

Xavier Adhoute et al. Hepatol Commun. 2022 Dec.

Abstract

This new UHPI score identifies three groups with different prognosis, but with no clear therapeutic guidance. Moreover, this model's predictive ability is now challenged in the era of combination therapies where durable responses are more commonly observed, and where response criteria remain to be defined.

PubMed Disclaimer

Conflict of interest statement

Xavier Adhoute consults for Bayer and Servier; he consults for and received grants from Ipsen, Mylan Medical, and Gilead. Thomas Wolf has nothing to report.

Figures

FIGURE 1
FIGURE 1
Patients with unresectable hepatocellular carcinoma being treated with atezolizumab–bevacizumab (n = 35). *indicates patients with ongoing treatment; the arrow indicates patients with radiologic response and higher scores; RR is according to the modified Response Evaluation Criteria in Solid Tumors. AE, adverse event; BCLC, Barcelona Clinic Liver Cancer; NIACE, nodularity, infiltrative, alpha‐fetoprotein, Child‐Pugh stage, Eastern Cooperative Oncology Group performance; PD, progressive disease; RR, radiologic response; SD, stable disease; UHPI, unresectable hepatocellular carcinoma prognostic index.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Demirtas CO, Ricco G, Ozdogan OC, Baltacioglu F, Ones T, Yumuk PF, et al. Proposal and validation of a novel scoring system for hepatocellular carcinomas beyond curability borders. Hepatol Commun. 2022;6:633–45. - PMC - PubMed
    1. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112–9. - PubMed
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. - PubMed

MeSH terms

Substances